Evidence map›Paper›PMID 24267727›Full record

ArticleBMC genomics2013

The chromatin modification by SUMO-2/3 but not SUMO-1 prevents the epigenetic activation of key immune-related genes during Kaposi's sarcoma associated herpesvirus reactivation.

Pei-Ching Chang, Chia-Yang Cheng, Mel Campbell, Yi-Cheng Yang, Hung-Wei Hsu, Ting-Yu Chang, Chia-Han Chu, Yi-Wei Lee, Chiu-Lien Hung, Shi-Mei Lai and 6 more

Open access · goldAbstract read
In one paragraph

Article in BMC genomics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Review
  7. In Vitro SUMOylation Assay to Study SUMO E3 Ligase Activity.Journal of visualized experiments : JoVE · 2018
    Article
  8. Viral manipulation of the cellular sumoylation machinery.Cell communication and signaling : CCS · 2017
    Review
  9. SUMO and the robustness of cancer.Nature reviews. Cancer · 2017
    Review
  10. Article
  11. Viral Interplay with the Host Sumoylation System.Advances in experimental medicine and biology · 2017
    Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Pei-Ching ChangInstitute of Microbiology and Immunology, National Yang-Ming University, Taipei 11221, Taiwan. pcchang@ym.edu.tw.
Chia-Yang Cheng
Mel Campbell
Yi-Cheng Yang
Hung-Wei Hsu
Ting-Yu Chang
Chia-Han Chu
Yi-Wei Lee
Chiu-Lien Hung
Shi-Mei Lai
Clifford G Tepper
Wen-Ping Hsieh
Hsei-Wei Wang
Chuan-Yi Tang
Wen-Ching Wang
Hsing-Jien Kung
National Tsing Hua University · TWNational Yang Ming Chiao Tung University · TWNational Health Research Institutes · TWUniversity of California, Davis · US

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI Laura Marcu · 2002 to 2026
$84.9M
NCI NIH HHS P30 CA093373
6 · The paper itself

Abstract

backgroundSUMOylation, as part of the epigenetic regulation of transcription, has been intensively studied in lower eukaryotes that contain only a single SUMO protein; however, the functions of SUMOylation during mammalian epigenetic transcriptional regulation are largely uncharacterized. Mammals express three major SUMO paralogues: SUMO-1, SUMO-2, and SUMO-3 (normally referred to as SUMO-1 and SUMO-2/3). Herpesviruses, including Kaposi's sarcoma associated herpesvirus (KSHV), seem to have evolved mechanisms that directly or indirectly modulate the SUMO machinery in order to evade host immune surveillance, thus advancing their survival. Interestingly, KSHV encodes a SUMO E3 ligase, K-bZIP, with specificity toward SUMO-2/3 and is an excellent model for investigating the global functional differences between SUMO paralogues.

resultsWe investigated the effect of experimental herpesvirus reactivation in a KSHV infected B lymphoma cell line on genomic SUMO-1 and SUMO-2/3 binding profiles together with the potential role of chromatin SUMOylation in transcription regulation. This was carried out via high-throughput sequencing analysis. Interestingly, chromatin immunoprecipitation sequencing (ChIP-seq) experiments showed that KSHV reactivation is accompanied by a significant increase in SUMO-2/3 modification around promoter regions, but SUMO-1 enrichment was absent. Expression profiling revealed that the SUMO-2/3 targeted genes are primarily highly transcribed genes that show no expression changes during viral reactivation. Gene ontology analysis further showed that these genes are involved in cellular immune responses and cytokine signaling. High-throughput annotation of SUMO occupancy of transcription factor binding sites (TFBS) pinpointed the presence of three master regulators of immune responses, IRF-1, IRF-2, and IRF-7, as potential SUMO-2/3 targeted transcriptional factors after KSHV reactivation.

conclusionOur study is the first to identify differential genome-wide SUMO modifications between SUMO paralogues during herpesvirus reactivation. Our findings indicate that SUMO-2/3 modification near protein-coding gene promoters occurs in order to maintain host immune-related gene unaltered during viral reactivation.

Indexed as

SumoylationVirus ActivationCell Line, TumorChromatinChromatin ImmunoprecipitationEpigenesis, GeneticGene OntologyGenes, MHC Class IIHEK293 CellsHerpesvirus 8, HumanHumansInterferon Regulatory FactorsPromoter Regions, GeneticProtein BindingSmall Ubiquitin-Related Modifier ProteinsTranscription FactorsChromatinInterferon Regulatory FactorsSmall Ubiquitin-Related Modifier ProteinsSUMO2 protein, humanSUMO3 protein, humanTranscription FactorsUbiquitins

Identifiers

PMID24267727
PMCPMC4046822
OpenAlexW2028371646

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.